DNMT1 and myelodysplastic syndrome: Hydralazine—an arterial vasodilator and a DNA methyltransferase (DNMT) inhibitor—is among these AHAs and has been repurposed for the treatment of T-cell leukemia [17], cutaneous T-cell lymphoma [18], and myelodysplastic syndrome (MDS) [18,19].